ABSTRACT
Objective To discuss intervention effects of Buyang Huanwu decoction on pulmonary fibrosis (PF) rats. Methods Totally 144 healthy male SD rats were randomly divided into six groups:sham-operation group, model group, prednisone group, Buyang Huanwu decoction high-, medium-, low-dose groups, 24 rats in each group. Except for sham-operation group, the rest groups were given injection of BLM via tracheal intubation for the establishment of PF model, while sham-operation group was instilled the same amount of NS. From the second day, all the rats received a gavage by related medicine. Eight rats in each group were killed respectively on day 7, 14 and 28 after intratracheal instillation. The contents of PCⅢ and Ⅳ-C in blood serum of experimental rats were tested by radioimmanoassay method. Results Compared with the sham-operation group, the contents of PCⅢ and Ⅳ-C in blood serum of other groups increased gradually, and that of the model group was the most obvious (P<0.01). Compared with the model group, each medicine group had different decreases in the contents of PCⅢ and Ⅳ-C in blood serum (P<0.01). Compared with the prednisone group, the contents of PCⅢ and Ⅳ-C in blood serum of Buyang Huanwu decoction medium-dose group obviously decreased on the 14th and 28th day (P<0.05), as well as that of Buyang Huanwu decoction low-dose group on the 28th day (P<0.05). Conclusion Buyang Huanwu decoction could effectively reduce proliferation of collagen fibers and excess deposition of ECM in lung tissue of PF, and played an anti-fibrosis effect on lungs.
ABSTRACT
The patients with dedifferentiated thyroid carcinoma were induced by all-trans retinoic acid (ATRA). The treatment was effective in 5 patients (5/9,55.6%), and 5 patients were benefited from following 131 I treatment(5/8, 62.5% ). Three patients(3/12,25.0% ) quitted because of neurological side-effects. It is efficacious to apply ATRA to induce dedifferentiated thyroid carcinoma and improve radio-iodine uptake and acquire benefit for patients, but clinic application of ATRA must be cautious.
ABSTRACT
<p><b>BACKGROUND</b>To study the clinical effects of ¹⁵³Sm-EDTMP plus chemotherapy in the treatment of bone metastasis of lung cancer.</p><p><b>METHODS</b>One hundred and ten lung cancer patients with one metastasis [male 82 and female 28, aged from 32 to 76 yrs; squamous cell carcinoma 28, adenocarcinoma 27, small cell lung cancer (SCLC) 7, mix type 41, alveolar carcinoma 7] who did not undergo an operation were entered into this study. The patients were divided into 3 groups: ¹⁵³Sm-EDTMP therapy only (37 cases), ¹⁵³Sm-EDTMP plus chemotherapy after 3 days (42 cases), 30 days after chemotherapy plus ¹⁵³Sm-EDTMP (31 cases). The dosages of ¹⁵³Sm-EDTMP ranged from 1 111 to 2 660 MBq. The patients with SCLC were adapted CCNU, MTX and CTX; those with non-small cell lung cancer (NSCLC) were adapted MMC, VCR and DDP. Statistic analysis of the data was performed by Chi-square test.</p><p><b>RESULTS</b>Total pain relief rate for ¹⁵³Sm-EDTMP only was 89.2% , for ¹⁵³Sm-EDTMP plus chemotherapy was 92.8%, and for chemotherapy plus 153 Sm EDTMP was 90.3% . The foci disappeared in 9 cases with ¹⁵³Sm-EDTMP only, in 12 cases with ¹⁵³Sm-EDTMP plus chemotherapy, and in 9 cases with chemotherapy plus ¹⁵³Sm-EDTMP. The 1 year survival rate was 29.7%(11/37) by 153 Sm only, 40.5%(17/42) by 153 Sm plus chemotherapy, 38.7%(12/31) by chemotherapy plus ¹⁵³Sm-EDTMP.</p><p><b>CONCLUSIONS</b>¹⁵³Sm-EDTMP plus chemotherapy is effective in the treatment of bone metastasis of lung cancer.</p>
ABSTRACT
The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.